Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging

JCI Insight

Volumn 1, Issue 14, 2016, Pages

  DuPont, Jennifer J ^a   McCurley, Amy ^a   Davel, Ana P ^a,b   McCarthy, Joseph ^a   Bender, Shawn B ^c,d,e   Hong, Kwangseok ^c,f   Yang, Yan ^c   Yoo, Jeung Ki ^g   Aronovitz, Mark ^a   Baur, Wendy E ^a   Christou, Demetra D ^g   Hill, Michael A ^c,f   Jaffe, Iris Z ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF MISSOURI   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f University of Missouri   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85019967643     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.88942     Document Type: Article

References (70)

1. Barton M, Husmann M, Meyer MR. Accelerated Vascular Aging as a Paradigm for Hypertensive Vascular Disease: Prevention and Therapy. Can J Cardiol. 2016;32(5):680–686.e4.
2. Gradman AH. Role of angiotensin II type 1 receptor antagonists in the treatment of hypertension in patients aged >or=65 years. Drugs Aging. 2009;26(9):751–767.
3. Hyman DJ, Taffet GE. Blood pressure control in the elderly: can you have too much of a good thing?. Curr Hypertens Rep. 2009;11(5):337–342.
4. Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci. 2010;65(10):1028–1041.
5. Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–717.
6. Armstrong C, Joint National Committee. JNC8 guidelines for the management of hypertension in adults. Am Fam Physician. 2014;90(7):503–504.
7. SPRINT Research Group, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103–2116.
8. Williamson JD, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA. 2016;315(24):2673–2682.
9. Bitzer M, Wiggins J. Aging Biology in the Kidney. Adv Chronic Kidney Dis. 2016;23(1):12–18.
10. Joseph BK, Thakali KM, Moore CL, Rhee SW. Ion channel remodeling in vascular smooth muscle during hypertension: Implications for novel therapeutic approaches. Pharmacol Res. 2013;70(1):126–138.
11. Wang M, Monticone RE, Lakatta EG. Arterial aging: a journey into subclinical arterial disease. Curr Opin Nephrol Hypertens. 2010;19(2):201–207.
12. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME. Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol. 2007;27(4):799–805.
13. Jaffe IZ, et al. Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest. 2010;120(11):3891–3900.
14. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96(6):643–650.
15. McCurley A, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012;18(9):1429–1433.
16. Dimmeler S, Nicotera P. MicroRNAs in age-related diseases. EMBO Mol Med. 2013;5(2):180–190.
17. Noren Hooten N, Abdelmohsen K, Gorospe M, Ejiogu N, Zonderman AB, Evans MK. microRNA expression patterns reveal differential expression of target genes with age. PLoS One. 2010;5(5):e10724.
18. Krug AW, et al. Elevated mineralocorticoid receptor activity in Aged Rat vascular smooth muscle cells Promotes a Proinflammatory Phenotype Via ERK1/2 MAPK and EGFR-Dependent Pathways. Hypertension. 2010;55(6):1476–1483.
19. Chen NX, et al. Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD). PLoS One. 2013;8(5):e64558.
20. Zheng L, et al. MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts. Biochem Biophys Res Commun. 2010;400(4):483–488.
21. Poduri A, et al. Regional variation in aortic AT1b receptor mRNA abundance is associated with contractility but unrelated to atherosclerosis and aortic aneurysms. PLoS One. 2012;7(10):e48462.
22. Hill MA, Davis MJ, Meininger GA, Potocnik SJ, Murphy TV. Arteriolar myogenic signalling mechanisms: Implications for local vascular function. Clin Hemorheol Microcirc. 2006;34(1-2):67–79.
23. Hwang MH, et al. Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clin Sci. 2013;125(11):513–520.
24. Lee S, Choi E, Cha MJ, Park AJ, Yoon C, Hwang KC. Impact of miRNAs on cardiovascular aging. J Geriatr Cardiol. 2015;12(5):569–574.
25. Bretschneider M, et al. Activated mineralocorticoid receptor regulates micro-RNA-29b in vascular smooth muscle cells. FASEB J. 2016;30(4):1610–1622.
26. Yin Q, Wang X, McBride J, Fewell C, Flemington E. B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J Biol Chem. 2008;283(5):2654–2662.
27. Onyeagucha BC, Mercado-Pimentel ME, Hutchison J, Flemington EK, Nelson MA. S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer. Exp Cell Res. 2013;319(13):2081–2090.
28. Bender SB, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?. Diabetes. 2013;62(2):313–319.
29. Bender SB, et al. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension. 2015;65(5):1082–1088.
30. Ratman D, et al. How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol Cell Endocrinol. 2013;380(1-2):41–54.
31. Chinenov Y, Gupte R, Rogatsky I. Nuclear receptors in inflammation control: repression by GR and beyond. Mol Cell Endocrinol. 2013;380(1-2):55–64.
32. Biddie SC, et al. Transcription factor AP1 potentiates chromatin accessibility and glucocorticoid receptor binding. Mol Cell. 2011;43(1):145–155.
33. Nagase M, Fujita T. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol. 2013;9(2):86–98.
34. Ceolotto G, et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens. 2011;24(2):241–246.
35. Pratt PF, Bonnet S, Ludwig LM, Bonnet P, Rusch NJ. Upregulation of L-type Ca2+ channels in mesenteric and skeletal arteries of SHR. Hypertension. 2002;40(2):214–219.
36. Kazda S, Garthoff B, Luckhaus G. Calcium and malignant hypertension in animal experiment: effects of experimental manipulation of calcium influx. Am J Nephrol. 1986;6 Suppl 1:145–150.
37. Suzuki H, Zweifach BW, Schmid-Schönbein GW. Glucocorticoid modulates vasodilator response of mesenteric arterioles in spontaneously hypertensive rats. Hypertension. 1996;27(1):114–118.
38. Falcone JC, Granger HJ, Meininger GA. Enhanced myogenic activation in skeletal muscle arterioles from spontaneously hypertensive rats. Am J Physiol. 1993;265(6 Pt 2):H1847–H1855.
39. Arii T, Ohyanagi M, Shibuya J, Iwasaki T. Increased function of the voltage-dependent calcium channels, without increase of Ca2+ release from the sarcoplasmic reticulum in the arterioles of spontaneous hypertensive rats. Am J Hypertens. 1999;12(12 Pt 1-2):1236–1242.
40. Ohya Y, Abe I, Fujii K, Takata Y, Fujishima M. Voltage-dependent Ca2+ channels in resistance arteries from spontaneously hypertensive rats. Circ Res. 1993;73(6):1090–1099.
41. Cox RH, Lozinskaya IM. Augmented calcium currents in mesenteric artery branches of the spontaneously hypertensive rat. Hypertension. 1995;26(6 Pt 2):1060–1064.
42. Lozinskaya IM, Cox RH. Effects of age on Ca2+ currents in small mesenteric artery myocytes from Wistar-Kyoto and spontaneously hypertensive rats. Hypertension. 1997;29(6):1329–1336.
43. Ohya Y, Tsuchihashi T, Kagiyama S, Abe I, Fujishima M. Single L-type calcium channels in smooth muscle cells from resistance arteries of spontaneously hypertensive rats. Hypertension. 1998;31(5):1125–1129.
44. Sun HX, et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension. 2012;60(6):1407–1414.
45. Vigorito E, Kohlhaas S, Lu D, Leyland R. miR-155: an ancient regulator of the immune system. Immunol Rev. 2013;253(1):146–157.
46. Caballero-Garrido E, et al. In Vivo Inhibition of miR-155 Promotes Recovery after Experimental Mouse Stroke. J Neurosci. 2015;35(36):12446–12464.
47. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date [published online ahead of print June 14, 2016]. Pharm Res. doi:10.1007/s11095.016.1958-5.
48. Kwon EJ, Skalak M, Lo Bu R, Bhatia SN. A neuron-targeted nanoparticle for siRNA delivery to traumatic brain injuries [published online ahead of print July 18, 2016]. ACS Nano. doi: 10.1021/acsnano.6b03858.
49. Swain S, Babu SM, Beg S, Jena J. Nanoparticles for cancer targeting: Current and Future Directions [published online ahead of print July 13, 2016]. Curr Drug Deliv.
50. Sundaramoorthy P, Ramasamy T, Mishra SK, Jeong KY, Yong CS, Kim JO, Kim HM. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells [published online ahead of print July 6, 2016]. Acta Biomater. doi: 10.1016/j.actbio.2016.07.006.
51. Iqbal J, Parviz Y, Pitt B, Newell-Price J, Al-Mohammad A, Zannad F. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur J Heart Fail. 2014;16(2):143–150.
52. Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich). 2007;9(1 Suppl 1):19–24.
53. Herrera M, Sparks MA, Alfonso-Pecchio AR, Harrison-Bernard LM, Coffman TM. Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein. Hypertension. 2013;61(1):253–258.
54. dos Santos RL, da Silva FB, Ribeiro RF, Stefanon I. Sex hormones in the cardiovascular system. Horm Mol Biol Clin Investig. 2014;18(2):89–103.
55. Hay M. Sex, the brain and hypertension: brain oestrogen receptors and high blood pressure risk factors. Clin Sci. 2016;130(1):9–18.
56. Glicklich D, Frishman WH. Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists. Drugs. 2015;75(5):473–485.
57. Clark D, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012;28(3):318–325.
58. Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–264.
59. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307–315.
60. Gentleman RC, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
61. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995:57(1):289-300.
62. R Development Core Team. The R Project for Statistical Computing. http://www.R-project.org. Accessed: August 3, 2016.
63. Newfell BG, et al. Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways. Arterioscler Thromb Vasc Biol. 2011;31(8):1871–1880.
64. Arriza JL, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237(4812):268–275.
65. Lombès M, Binart N, Oblin ME, Joulin V, Baulieu EE. Characterization of the interaction of the human mineralocorticosteroid receptor with hormone response elements. Biochem J. 1993;292(Pt 2):577–583.
66. Barrett Mueller K, et al. Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology. 2014;155(11):4461–4472.
67. Yang Y, et al. Heterogeneity in function of small artery smooth muscle BKCa: involvement of the beta1-subunit. J Physiol (Lond). 2009;587(Pt 12):3025–3044.
68. Moessler H, Mericskay M, Li Z, Nagl S, Paulin D, Small JV. The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. Development. 1996;122(8):2415–2425.
69. Lovren F, et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation. 2012;126(11 Suppl 1):S81–S90.
70. Wendling O, Bornert JM, Chambon P, Metzger D. Efficient temporally-controlled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis. 2009;47(1):14–18.